Paul-Ehrlich-Institut and Robert Koch-Institut support the clinical development of vaccines and therapeutic medicines against Ebola
On August 8, 2014, the WHO declared the ongoing Ebola epidemic an International Public-Health Emergency. In recent years, several promising approaches to combat Ebola virus infection have emerged as a result of research and development on vaccines and therapeutic medicines. In non-clinical experiments protection of naïve animals from infection or reduction of disease severity in already infected animals has been shown. Now is the time to accelerate clinical development of these candidate vaccines and therapeutics by moving them into clinical trials involving human participants. This is unrelated to the compassionate use applications to save individual patients. The Paul-Ehrlich-Institut offers regulatory support to interested parties via early advice by its Innovation Office.
Stumbling stones – for scientists who suffered from the atrocities of the NS regime: Georg-Speyer-Haus and Paul-Ehrlich-Institut remember their Jewish members of staff
On June, 23, 2014, at 5:00 p.m., Gunter Demnig, the initiator of the project "Stumbling Stones" will lay more stumbling stones before the Georg-Speyer-Haus at Frankfurt in memory of former members of staff of the Georg-Speyer-Haus and the Paul-Ehrlich-Institut. Prior to this, a public commemorative event will take place in the lecture hall of the Georg-Speyer-Haus at 4:30 p.m.
Measles – new inhibitor found effective in large animal model may help control local outbreaks
A newly developed candidate drug against measles virus is effective in an animal model. During measles outbreaks, this compound may protect contacts of infected individuals from clinical signs and prevent virus dissemination.